A combined biomarker and clinical panel for chronic graft versus host disease diagnosis.

Autor: Pidala J; Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute Tampa FL USA., Sigdel TK; Department of Surgery University of California San Francisco San Francisco CA USA., Wang A; Department of Surgery University of California San Francisco San Francisco CA USA., Hsieh S; Department of Surgery University of California San Francisco San Francisco CA USA., Inamoto Y; Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA., Martin PJ; Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA., Flowers ME; Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA., Hansen JA; Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA., Lee SJ; Clinical Research Division Fred Hutchinson Cancer Research Center Seattle WA USA., Sarwal MM; Department of Surgery University of California San Francisco San Francisco CA USA.
Jazyk: angličtina
Zdroj: The journal of pathology. Clinical research [J Pathol Clin Res] 2016 Nov 29; Vol. 3 (1), pp. 3-16. Date of Electronic Publication: 2016 Nov 29 (Print Publication: 2017).
DOI: 10.1002/cjp2.58
Abstrakt: Whilst many chronic graft versus host disease (cGVHD) biomarkers have been previously reported, few have been verified in an independent cGVHD cohort. We aimed to verify the diagnostic accuracy of previously reported markers of cGVHD in a multi-centre Chronic GVHD Consortium. A total of 42 RNA and 18 protein candidate biomarkers were assessed amongst 59 cGVHD cases and 33 matched non-GVHD controls. Total RNA was isolated from PBMC, and RNA markers were quantified using PCR. Serum protein markers were quantified using ELISA. A combined 3 RNA biomarker (IRS2, PLEKHF1 and IL1R2) and 2 clinical variables (recipient CMV serostatus and conditioning regimen intensity) panel accurately (AUC 0.81) segregated cGVHD cases from controls. Other studied RNA and protein markers were not confirmed as accurate cGVHD diagnostic biomarkers. The studied markers failed to segregate higher risk cGVHD (per overall NIH 0-3 score, and overlap versus classic cGVHD status). These data support the need for multiple independent verification studies for the ultimate clinical application of cGVHD diagnostic biomarkers.
Databáze: MEDLINE
Externí odkaz: